• admin@ataxiatelangiectasia.es
गतिभंग रक्त वाहिनी विस्तार
  • शुरू
  • ए-टी क्या है?

Bibliography

  • Ataxia telangiectasia, Menkes kinky hair disease and neurocutaneous melanosis.
    हिट्स: 174
    • Italy
    • 2017
    • G Ital Dermatol Venereol
    • Caccavale S
    • Bove D
    • Bove RM
    • LA Montagna M
    • neurocutaneous syndromes
    G Ital Dermatol Venereol. 2017 Feb;152(1):58-65. doi: 10.23736/S0392-0488.16.05083-5. Epub 2016 Mar 22.
    Caccavale S1, Bove D1, Bove RM1,2, LA Montagna M3.

    Author information

    1
    Department of Mental and Physical Health and Preventive Medicine, Second University of Naples, Naples, Italy.
    2
    Fusis Association for Research in Child and Adolescent Neuropsychiatry, Alvignano, Italy.
    3
    Section of Psychiatry and Clinical Psychology, Department of Clinical and Experimental Sciences, University of Foggia, Foggia, Italy - maddafly87@libero.it.

    Abstract

    This article explores three neurocutaneous syndromes (NCSs), i.e. genetic disorders producing developmental abnormalities of the skin and an increased risk of neurological complications. In this review, different aspects of ataxia telangiectasia, Menkes kinky hair disease and neurocutaneous melanosis are examined: clinical features, genetic defect, mutation spectrum, pathogenesis, and neurobiological basis; indications for clinical practice are also provided to the readers. The aim of this review is to stress the importance of cooperation among dermatologists, neurologists and psychiatrists, in order to provide patients suffering from these diseases with timely diagnosis and targeted treatments.

    PMID:
     
    27002302
     
    DOI:
     
    10.23736/S0392-0488.16.05083-5
    [Indexed for MEDLINE]
  • Magnetic resonance imaging of ataxia-telangiectasia.
    हिट्स: 211
    • United States of America
    • 2016
    • Neurol India
    • Zamora C
    • Yahyavi-Firouz-Abadi N
    • Kuyumcu G
    • Kontzialis M
    • Magnetic resonance imaging
    Neurol India. 2016 Mar-Apr;64 Suppl:S129. doi: 10.4103/0028-3886.178058.
    Zamora C, Yahyavi-Firouz-Abadi N, Kuyumcu G1, Kontzialis M.

    Author information

    1
    Division of Neuroradiology, Rush University Medical Center 1653 W, Congress Parkway, Chicago, IL 60612, USA.
    PMID:
     
    26954959
     
    DOI:
     
    10.4103/0028-3886.178058
    Free full text
  • Ataxia telangiectasia: a review.
    हिट्स: 187
    • 2016
    • Neurodegeneration
    • Purkinje cells
    • McGrath-Morrow SA
    • Lederman HM
    • Orphanet J Rare Dis
    • cerebellum
    • cancer
    • immunodeficiency
    • Lefton-Greif MA
    • Crawford TO
    • Rothblum-Oviatt C
    • Wright J
    • Dysphagia
    • Pulmonary disease
    • review
    Orphanet J Rare Dis. 2016 Nov 25;11(1):159.

    Ataxia telangiectasia: a review.

    Rothblum-Oviatt C1, Wright J2, Lefton-Greif MA3, McGrath-Morrow SA3, Crawford TO4, Lederman HM5.

    Author information

    1
    A-T Children's Project, Coconut Creek, Florida, USA. cynthia@atcp.org.
    2
    The Ataxia Telangiectasia Clinical Center, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA.
    3
    The Ataxia Telangiectasia Clinical Center, Departments of Pediatrics and Pediatric Respiratory Sciences, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA.
    4
    The Ataxia Telangiectasia Clinical Center, Departments of Pediatrics and Neurology, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA.
    5
    The Ataxia Telangiectasia Clinical Center, Departments of Pediatrics, Medicine and Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA.

    Abstract

    DEFINITION OF THE DISEASE:

    Ataxia telangiectasia (A-T) is an autosomal recessive disorder primarily characterized by cerebellar degeneration, telangiectasia, immunodeficiency, cancer susceptibility and radiation sensitivity. A-T is often referred to as a genome instability or DNA damage response syndrome.

    EPIDEMIOLOGY:

    The world-wide prevalence of A-T is estimated to be between 1 in 40,000 and 1 in 100,000 live births.

    CLINICAL DESCRIPTION:

    A-T is a complex disorder with substantial variability in the severity of features between affected individuals, and at different ages. Neurological symptoms most often first appear in early childhood when children begin to sit or walk. They have immunological abnormalities including immunoglobulin and antibody deficiencies and lymphopenia. People with A-T have an increased predisposition for cancers, particularly of lymphoid origin. Pulmonary disease and problems with feeding, swallowing and nutrition are common, and there also may be dermatological and endocrine manifestations.

    ETIOLOGY:

    A-T is caused by mutations in the ATM (Ataxia Telangiectasia, Mutated) gene which encodes a protein of the same name. The primary role of the ATM protein is coordination of cellular signaling pathways in response to DNA double strand breaks, oxidative stress and other genotoxic stress.

    DIAGNOSIS:

    The diagnosis of A-T is usually suspected by the combination of neurologic clinical features (ataxia, abnormal control of eye movement, and postural instability) with one or more of the following which may vary in their appearance: telangiectasia, frequent sinopulmonary infections and specific laboratory abnormalities (e.g. IgA deficiency, lymphopenia especially affecting T lymphocytes and increased alpha-fetoprotein levels). Because certain neurological features may arise later, a diagnosis of A-T should be carefully considered for any ataxic child with an otherwise elusive diagnosis. A diagnosis of A-T can be confirmed by the finding of an absence or deficiency of the ATM protein or its kinase activity in cultured cell lines, and/or identification of the pathological mutations in the ATM gene.

    DIFFERENTIAL DIAGNOSIS:

    There are several other neurologic and rare disorders that physicians must consider when diagnosing A-T and that can be confused with A-T. Differentiation of these various disorders is often possible with clinical features and selected laboratory tests, including gene sequencing.

    ANTENATAL DIAGNOSIS:

    Antenatal diagnosis can be performed if the pathological ATM mutations in that family have been identified in an affected child. In the absence of identifying mutations, antenatal diagnosis can be made by haplotype analysis if an unambiguous diagnosis of the affected child has been made through clinical and laboratory findings and/or ATM protein analysis.

    GENETIC COUNSELING:

    Genetic counseling can help family members of a patient with A-T understand when genetic testing for A-T is feasible, and how the test results should be interpreted.

    MANAGEMENT AND PROGNOSIS:

    Treatment of the neurologic problems associated with A-T is symptomatic and supportive, as there are no treatments known to slow or stop the neurodegeneration. However, other manifestations of A-T, e.g. immunodeficiency, pulmonary disease, failure to thrive and diabetes can be treated effectively.

    KEYWORDS:

    Cancer; Cerebellum; Dysphagia; Immunodeficiency; Neurodegeneration; Pulmonary disease; Purkinje cells

    PMID:
     
    27884168
     
    PMCID:
     
    PMC5123280
     
    DOI:
     
    10.1186/s13023-016-0543-7
    [Indexed for MEDLINE] 
    Free PMC Article
  • Endocrine abnormalities in ataxia telangiectasia: findings from a national cohort.
    हिट्स: 154
    • Israel
    • Nissenkorn A
    • Sarouk I
    • Lahad A
    • 2016
    • Pediatr Res
    • Levy-Shraga Y
    • Banet-Levi Y
    • Modan-Moses D
    • endocrinology
    Pediatr Res. 2016 Jun;79(6):889-94. doi: 10.1038/pr.2016.19. Epub 2016 Feb 18.
    Nissenkorn A1,2, Levy-Shraga Y2,3, Banet-Levi Y4, Lahad A5, Sarouk I6, Modan-Moses D2,3.

    Author information

    1
    Service for Rare Disorders, Pediatric Neurology Unit, The Edmond and Lilly Safra Children's Hospital, Sheba Medical Center, Ramat Gan, Israel.
    2
    The Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
    3
    Pediatric Endocrinology and Diabetes Unit, The Edmond and Lilly Safra Children's Hospital, Sheba Medical Center, Ramat Gan, Israel.
    4
    The National Ataxia-Telangiectasia Clinic, The Edmond and Lilly Safra Children's Hospital, Sheba Medical Center, Ramat Gan, Israel.
    5
    Division of Pediatric Gastroenterology and Nutrition, Safra Children's Hospital, Sheba Medical Center, Tel-Hashomer, Israel.
    6
    Pediatric Pulmonary Unit, The Edmond and Lilly Safra Children's Hospital, Sheba Medical Center, Ramat Gan, Israel.

    Abstract

    BACKGROUND:

    Ataxia telangiectasia (AT) is a genetic multisystem disorder, presenting with progressive ataxia, immune deficiency, and propensity toward malignancy. Endocrine abnormalities (growth retardation, reproductive dysfunction, and diabetes) have been described, however detailed information regarding this aspect is lacking. We aimed to characterize endocrine anomalies and growth patterns in a large cohort of AT patients.

    METHODS:

    Retrospective study comprising all 52 patients (aged 2-26.2 y) followed at a national AT Clinic. Anthropometric and laboratory measurements were extracted from the charts.

    RESULTS:

    Median height-SDS was already subnormal during infancy, remaining negative throughout follow up to adulthood. Height-SDS was more impaired than weight-SDS up to age 4 y, thereafter weight-SDS steadily decreased, resulting in progressively lower BMI-SDS. IGF-I-SDS was low (-1.53 ± 1.54), but did not correlate with height-SDS. Gonadal failure was present in all 13 females older than 10 y but only in one male. Two patients had diabetes and 10 had dyslipidemia. Vitamin D deficiency was observed in 52.2% of the evaluated patients.

    CONCLUSION:

    Our results suggest a primary growth abnormality in AT, rather than secondary to nutritional impairment or disease severity. Sex hormone replacement should be considered for female patients. Vitamin D levels should be followed and supplementation given if needed.

    PMID:
     
    26891003
     
    DOI:
     
    10.1038/pr.2016.19
    [Indexed for MEDLINE]
  • Medical Management of Pediatric Malignant Bowel Obstruction in a Patient with Burkitt's Lymphoma and Ataxia Telangiectasia Using Continuous Ambulatory Drug Delivery System.
    हिट्स: 179
    • ataxia telangiectasia
    • 2018
    • J Pain Palliat Care Pharmacother
    • Ghoshal A
    • Salins N
    • Damani A
    • Deodhar J
    • Muckaden MA
    • Burkitt's lymphoma
    • continuous ambulatory drug delivery system
    • palliative care
    • pediatric malignant bowel obstruction
    J Pain Palliat Care Pharmacother. 2016;30(1):44-8. doi: 10.3109/15360288.2015.1134748. Epub 2016 Feb 10.
    Ghoshal A, Salins N, Damani A, Deodhar J, Muckaden MA.

    Abstract

    Malignant bowel obstruction (MBO) is commonly seen in patients with advanced abdominal cancers. The incidence of pediatric MBO in a patient with Burkitt's lymphoma and ataxia telangiectasia is rare, with no published case reports till now. Conservative management of inoperable MBO results in relief of symptoms and improves quality of life. An 11-year-old boy with Burkitt's lymphoma and ataxia telangiectasia was referred to pediatric palliative care with MBO. The objective of this report is to demonstrate conservative management of pediatric MBO using continuous ambulatory drug delivery system. The patient was initiated on continuous ambulatory drug delivery (CADD) system for symptom relief. MBO was reversed with conservative management and the child was discharged on self-collapsible portable elastomeric continuous infusion pump under the supervision of a local family physician. The child remained comfortable at home for 4 weeks until his death. His parents were satisfied with the child's symptom control, quality of life, and were able to care for the child at home. In a resource-limited setting, managing patients at home using elastomeric continuous infusion pumps instead of expensive automated CADD is a practical pharmacoeconomic approach.

    KEYWORDS:

    Ataxia telangiectasia; Burkitt's lymphoma; continuous ambulatory drug delivery system; palliative care; pediatric malignant bowel obstruction

    PMID:
     
    26862790
     
    DOI:
     
    10.3109/15360288.2015.1134748
    [Indexed for MEDLINE]
  • Childhood colon cancer in a patient with ataxia telangiectasia.
    हिट्स: 192
    • ataxia telangiectasia
    • 2016
    • cancer
    • case
    • Ann Transl Med
    • Korea
    • Jo KM
    • Yang SY
    • Park JH
    • Kim TO
    • Jeong HJ
    • Heo CM
    • Jang JH
    • Hur SC
    • Jeong NR
    • Jeong SJ
    • Seol SH
    • Nam KH
    • childhood colon cancer
    • signet ring cell
    Ann Transl Med. 2016 Jan;4(1):11. doi: 10.3978/j.issn.2305-5839.2015.12.59.

    Childhood colon cancer in a patient with ataxia telangiectasia.

    Jo KM1, Yang SY1, Park JH1, Kim TO1, Jeong HJ1, Heo CM1, Jang JH1, Hur SC1, Jeong NR1, Jeong SJ1, Seol SH1, Nam KH1.

    Author information

    1
    1 Department of Internal Medicine, 2 Department of Pathology, Haeundae Paik Hospital, Inje University College of Medicine, Busan 48108, Korea.

    Abstract

    BACKGROUND:

    Ataxia-telangiectasia (AT) is a rare autosomal recessive disease characterized by progressive neurologic impairment and cerebellar ataxia. In addition, patients with this disease are known to have an inherent increased susceptibility to the development of cancer, predominantly hematologic malignancies.

    METHODS:

    We report the case of a young boy with AT from Russia, who had abdominal pain. Laboratory tests and radiologic examinations were performed to him.

    RESULTS:

    After abdominal computed tomography (CT), colonoscopy and surgical interventions, the young boy was diagnosed with colon cancer that had signet ring cell features.

    CONCLUSIONS:

    It is known that the patient with AT appeared to be predisposed to various tumors, including leukemia or lymphoma, which are more common in childhood. Even if the patient with AT could have solid tumor such as stomach cancer or breast cancer, it is less likely to have colon cancer, especially signet ring cell type. Actually, no case of colon cancer has ever been reported, especially in young patient and hence, we have focused on this point and are hereby reporting this unique case.

    KEYWORDS:

    Ataxia-telangiectasia (AT); childhood colon cancer; signet ring cell

    PMID:
     
    26855947
     
    PMCID:
     
    PMC4716938
     
    DOI:
     
    10.3978/j.issn.2305-5839.2015.12.59
    Free PMC Article
  • Ataxia-telangiectasia in the south of Tunisia: A study of 11 cases.
    हिट्स: 237
    • Tunisia
    • Tunis Med
    • Sfaihi L
    • Stoppa Lyonnet D
    • Ben Ameur S
    • Dubois D'enghien C
    • Kamoun T
    • Barbouch MR
    • Hachicha M
    • retrospective study
    Tunis Med. 2015 Aug-Sep;93(8-9):511-5.

    Ataxia-telangiectasia in the south of Tunisia: A study of 11 cases.

    Sfaihi L, Stoppa Lyonnet D, Ben Ameur S, Dubois D'enghien C, Kamoun T, Barbouch MR, Hachicha M.

    Abstract

    BACKGROUND:

    Ataxia-telangiectasia (A-T) is a multisystem disorder characterized by progressive neurologic impairment, variable immunodeficiency, impaired organ maturation, X-ray hypersensitivity, oculocutaneous telangiectasia, and a predisposition to malignancy.

    AIM:

    We performed this study in order to describe clinical, immunological and molecular features of patients with AT followed in the south of Tunisia Methods: we performed a retrospective study (1996-2012) in the south of Tunisia about all cases of A-T in order to describe their clinical, immunological and molecular features.

    RESULTS:

    11 cases of AT were found. The mean age at onset of symptoms was 20 months with extremes varying from 3 months to 4 years. The median time to diagnosis was 3.6 years (range: 0-12 years).The main clinical feature of cerebellar syndrome, ataxia, was present at diagnosis in 8 patients and occurred at mean ages of 2.8 years. Ocular telangiectasia occurred at a mean age of 3.9 years (extremes: 3 months and 7 years). Recurrent sino-pulmonary infections that affected 7 children occurred at the mean age of 4.3 years. The most common humoral immune abnormality was serum IgA deficiency. Lymphopenia was found in 7 cases and lack of CD4 T in 6 cases. Cytogenetic analyses showed chromosomal instability in all children and a translocation (7-14) in two patients. A molecular diagnosis established in 6 patients from 4 families showed 5 different mutations of ATM gene. After an average decline of 5 years and 6 months, 7 patients died of severe pulmonary infection. Among them, 3 were ATM mutated.

    CONCLUSION:

    Morbidity and mortality among patients with A- T are associated with ATM genotype.

    PMID:
     
    26815515
    [Indexed for MEDLINE] 
    Free full text
  • Treatment of EBV-associated nodular sclerosing Hodgkin lymphoma in a patient with ataxia telangiectasia with brentuximab vedotin and reduced COPP plus rituximab.
    हिट्स: 214
    • Germany
    • 2015
    • Voss S
    • non-Hodgkin lymphoma
    • Pediatr Blood Cancer
    • Meister MT
    • Schwabe D
    • Treatment
    • rituximab
    Pediatr Blood Cancer. 2015 Nov;62(11):2018-20. doi: 10.1002/pbc.25621. Epub 2015 Jun 24.
    Meister MT1, Voss S1, Schwabe D1.

    Author information

    1
    Pediatric Clinic, Pediatric Hematology and Oncology, Hospital of the Goethe-University Frankfurt, Frankfurt, Germany.

    Abstract

    Patients with ataxia telangiectasia (AT) with malignancies face poor prognosis due to increased treatment-related toxicity. Here, we report a 14-year-old male with AT and Hodgkin lymphoma (HL) who received brentuximab vedotin and reduced COPP plus rituximab courses. This treatment resulted in complete remission and showed no severe toxicity.

    KEYWORDS:

    Hodgkin lymphoma; ataxia telangiectasia; brentuximab vedotin

    Comment in

    • Reply to Comment on: Treatment of EBV-Associated Nodular Sclerosing Hodgkin Lymphoma in a Patient With Ataxia Telangiectasia With Brentuximab Vedotin and Reduced COPP Plus Rituximab. [Pediatr Blood Cancer. 2016]
    • Comment on: Treatment of EBV-Associated Nodular Sclerosing Hodgkin Lymphoma in a Patient With Ataxia Telangiectasia With Brentuximab Vedotin and Reduced COPP Plus Rituximab. [Pediatr Blood Cancer. 2016]
    PMID:
     
    26109475
     
    DOI:
     
    10.1002/pbc.25621
    [Indexed for MEDLINE]
  • Reply to Comment on: Treatment of EBV-Associated Nodular Sclerosing Hodgkin Lymphoma in a Patient With Ataxia Telangiectasia With Brentuximab Vedotin and Reduced COPP Plus Rituximab.
    हिट्स: 179
    • 2016
    • Voss S
    • non-Hodgkin lymphoma
    • Meister MT
    • Schwabe D
    • Treatment
    • rituximab
    • Brentuximab Vedotin
    Pediatr Blood Cancer. 2016 May;63(5):947. doi: 10.1002/pbc.25884. Epub 2016 Jan 6.
    Meister MT1, Voss S1, Schwabe D1.

    Author information

    1
    Pediatric Clinic, Pediatric Hematology and Oncology, Hospital of the Goethe-University Frankfurt, Frankfurt, Germany.

    Comment on

    • Treatment of EBV-associated nodular sclerosing Hodgkin lymphoma in a patient with ataxia telangiectasia with brentuximab vedotin and reduced COPP plus rituximab. [Pediatr Blood Cancer. 2015]
    • Comment on: Treatment of EBV-Associated Nodular Sclerosing Hodgkin Lymphoma in a Patient With Ataxia Telangiectasia With Brentuximab Vedotin and Reduced COPP Plus Rituximab. [Pediatr Blood Cancer. 2016]
    PMID:
     
    26739927
     
    DOI:
     
    10.1002/pbc.25884
    [Indexed for MEDLINE]
  • Corynebacterium propinquum bronchopneumonia in a child with ataxia telangiectasia.
    हिट्स: 185
    • ataxia telangiectasia
    • Turkey
    • 2016
    • case
    • Respiratory infections
    • Children
    • Turk J Pediatr
    • Malkoçoğlu G
    • Gencer H
    • Kaya A
    • Dalgıç N
    • Bulut ME
    • Aktaş E
    • bronchopneumonia
    Turk J Pediatr. 2016;58(5):558-561. doi: 10.24953/turkjped.2016.05.018.

    Malkoçoğlu G1, Gencer H2, Kaya A2, Dalgıç N2, Bulut ME1, Aktaş E1.

    Author information

    1
    Clinical Microbiology Laboratory, Şişli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey.
    2
    Department of Pediatrics, Şişli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey.

    Abstract

    Nondiphtherial Corynebacterium species isolated from clinical specimens are usually considered as contaminants by many clinicians when reported by microbiologists. However, an increasing number of studies have confirmed the importance of Corynebacterium spp. in the etiology of a variety of infectious processes. In this report, we present a case of bronchopneumonia caused by Corynebacterium propinquum. The infection occurred in a seven-year-old child who had a history of immunosuppression due to ataxia telangiectasia. The purulent sputum of the patient yielded a large number of polymorphonuclear leucocytes with abundant gram-positive coryneform bacilli in gram staining and pure growth of coryneform bacteria in culture. Definitive identification as C. propinquum was made by matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) and 16S rRNA gene sequencing. C. propinquum should be recognized as a potential pathogen and included in the etiologic diagnostic algorithm, particularly in patients with immunosuppressive conditions.

    KEYWORDS:

    Corynebacterium propinquum; ataxia telangiectasia; bronchopneumonia; child; gram staining

    PMID:
     
    28621102
     
    DOI:
     
    10.24953/turkjped.2016.05.018
    [Indexed for MEDLINE] 
    Free full text
  • An unusual manifestation: Papillary thyroid carcinoma in a patient with ataxia-telengiectasia.
    हिट्स: 166
    • Turkey
    • 2016
    • cancer
    • Turk J Pediatr
    • Ulusoy E
    • Edeer-Karaca N
    • Özen S
    • Ertan Y
    • Gökşen D
    • Aksu G
    • Darcan Ş
    • Kütükçüler N
    • Papillary thyroid carcinoma
    Turk J Pediatr. 2016;58(4):442-445.
    Ulusoy E1, Edeer-Karaca N1, Özen S1, Ertan Y2, Gökşen D1, Aksu G1, Darcan Ş1, Kütükçüler N1.

    Author information

    1
    Departments of Pediatrics, Ege University Faculty of Medicine, İzmir, Turkey.
    2
    Departments of Pathology, Ege University Faculty of Medicine, İzmir, Turkey.

    Abstract

    Ataxia-telangiectasia (A-T) is a rare autosomal recessive, multisystem, neurodegenerative disorder, characterized by oculocutaneous telangiectasias, variable immunodeficiency and progressive neurological impairment. Definitive diagnosis is made by revealing a disease causing mutation on ATM gene. Missense mutations and polymorphisms of ATM gene can play a role in the development of thyroid papillary carcinoma. A 13-year-old Turkish girl was diagnosed with ataxia telengiectasia at the age of 8 years. When she was 12 years old, multi-nodular goiter was detected by physical examination and ultrasonography. She underwent thyroidectomy and histopathologic investigation revealed a papillary carcinoma with follicular variant. The patient received post-operative radioiodine therapy as well as L-thyroxine treatment because she had residual lesions. Up until now, she is the first Turkish child wit A-T and thyroid carcinoma described in the literature.

    KEYWORDS:

    ataxia telengiectasia; papillary thyroid carcinoma

    PMID:
     
    28276222
    [Indexed for MEDLINE] 
    Free full text
  • Bladder Wall Telangiectasia in a Patient with Ataxia-Telangiectasia and How to Manage?
    हिट्स: 166
    • Turkey
    • case
    • Case Rep Pediatr
    • Aygün FD
    • Nepesov S
    • Çokuğraş H
    • Camcıoğlu Y
    • bladder wall
    • telangiectasia
    • cyclophosphamide
    • non-Hodgkin's lymphoma
    Case Rep Pediatr. 2015;2015:615368. doi: 10.1155/2015/615368. Epub 2015 Nov 29.
    Aygün FD1, Nepesov S1, Çokuğraş H1, Camcıoğlu Y1.

    Author information

    1
    Department of Pediatric Infectious Diseases, Clinical Immunology and Allergy, Istanbul University, Cerrahpasa Medical Faculty, 34098 Istanbul, Turkey.

    Abstract

    Ataxia-telangiectasia (A-T) is a rare neurodegenerative, inherited disease causing severe morbidity. Oculocutaneous telangiectasias are almost constant findings among the affected cases as telangiectasia is considered the main clinical finding for diagnosis. Vascular abnormalities in organs have been reported infrequently but bladder wall telangiectasias are extremely rare. We aimed to report recurrent hemorrhage from bladder wall telangiectasia in a 9-year-old boy with A-T who had received intravenous cyclophosphamide for non-Hodgkin's lymphoma. Since A-T patients are known to be more susceptible to chemical agents, we suggested that possibly cyclophosphamide was the drug which induced bladder wall injury in this patient.

    PMID:
     
    26693373
     
    PMCID:
     
    PMC4677013
     
    DOI:
     
    10.1155/2015/615368
    Free PMC Article
  • Novel ATM mutations with ataxia-telangiectasia.
    हिट्स: 159
    • ataxia telangiectasia
    • myoclonus
    • China
    • ATM
    • mutation
    • 2016
    • Neurosci Lett
    • Liu XL
    • Wang T
    • Huang XJ
    • Zhou HY
    • Luan XH
    • Shen JY
    • Chen SD
    • Cao L
    Neurosci Lett. 2016 Jan 12;611:112-5. doi: 10.1016/j.neulet.2015.11.036. Epub 2015 Nov 25.

    Liu XL1, Wang T1, Huang XJ1, Zhou HY1, Luan XH1, Shen JY1, Chen SD2, Cao L3.

    Author information

    1
    Department of Neurology, Rui Jin Hospital & Rui Jin Hospital North, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
    2
    Department of Neurology, Rui Jin Hospital & Rui Jin Hospital North, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China. Electronic address: chen_sd@medmail.com.cn.
    3
    Department of Neurology, Rui Jin Hospital & Rui Jin Hospital North, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China. Electronic address: caoli2000@yeah.net.

    Abstract

    Ataxia telangiectasia is an autosomal recessive multisystem disorder characterized by progressive cerebellar ataxia with onset in childhood, oculocutaneous telangiectasia, increased serum alpha-fetoprotein, immunodeficiency, chromosomal instability, and radiation hypersensitivity. Ataxia-telangiectasia mutated gene (ATM) is one of the known genes to be associated with ataxia telangiectasia. We reported the clinical and genetic findings of three early-onset Chinese patients who demonstrated ataxia, oculomotor apraxia, choreoathetosis, myoclonus and telangiectasia of eyes. Sequence analysis of ATM revealed two known nonsense mutations c.8287C>T and c.9139C>T in the siblings. Though the siblings carried the same mutations, they showed different clinical features involving strephenopodia, exotropia, torsion dystonia, myoclonus and extrapyramidal impairments. The other patient was compound heterozygotes for ATM: c.8911C>T and c.7141_7151delAATGGAAAAAT, both of which were not reported previously and not found in 200 control chromosomes. This study widens the spectrum of mutations and phenotypes in ataxia telangiectasia.

    KEYWORDS:

    ATM; Ataxia telangiectasia; Myoclonus; Novel mutation

    PMID:
     
    26628246
     
    DOI:
     
    10.1016/j.neulet.2015.11.036
    [Indexed for MEDLINE]
  • ERS statement on the multidisciplinary respiratory management of ataxia telangiectasia.
    हिट्स: 207
    • Germany
    • United Kingdom
    • Israel
    • 2015
    • multidisciplinary care
    • respiration
    • Eur Respir Rev
    • Switzerland
    Eur Respir Rev. 2015 Dec;24(138):565-81. doi: 10.1183/16000617.0066-2015.
    Bhatt JM1, Bush A2, van Gerven M3, Nissenkorn A4, Renke M5, Yarlett L6, Taylor M7, Tonia T8, Warris A9, Zielen S5, Zinna S10, Merkus PJ3; European Respiratory Society.

    Author information

    1
    Nottingham Children's Hospital, UK Paediatric National Clinic, Nottingham University Hospitals NHS Trust, Nottingham, UK jayeshbhatt@hotmail.com.
    2
    Imperial College and Royal Brompton Hospital, London, UK.
    3
    Dept of Paediatrics, Division of Respiratory Medicine, Amalia Children's Hospital Radboud, University Medical Centre, Nijmegen, The Netherlands.
    4
    Rare Diseases Service and Pediatric Neurology Unit, Edmond and Lilly Safra Pediatric Hospital, Sheba Medical Center, Tel HaShomer, Israel Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
    5
    Dept of Allergology, Pneumology and Cystic Fibrosis, Children's Hospital, Goethe-University Theodor-Stern Kai, Frankfurt/Main, Germany.
    6
    The A-T Society, IACR-Rothamsted, Harpenden, UK.
    7
    School of Cancer Sciences, University of Birmingham, Birmingham, UK.
    8
    Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
    9
    Institute of Medical Sciences, University of Aberdeen and the Royal Aberdeen Children's Hospital, Aberdeen, UK.
    10
    Nottingham Children's Hospital, UK Paediatric National Clinic, Nottingham University Hospitals NHS Trust, Nottingham, UK.

    Abstract

    Ataxia telangiectasia (A-T) is a rare, progressive, multisystem disease that has a large number of complex and diverse manifestations which vary with age. Patients with A-T die prematurely with the leading causes of death being respiratory diseases and cancer. Respiratory manifestations include immune dysfunction leading to recurrent upper and lower respiratory infections; aspiration resulting from dysfunctional swallowing due to neurodegenerative deficits; inefficient cough; and interstitial lung disease/pulmonary fibrosis. Malnutrition is a significant comorbidity. The increased radiosensitivity and increased risk of cancer should be borne in mind when requesting radiological investigations. Aggressive proactive monitoring and treatment of these various aspects of lung disease under multidisciplinary expertise in the experience of national multidisciplinary clinics internationally forms the basis of this statement on the management of lung disease in A-T. Neurological management is outwith the scope of this document.

    PMID:
     
    26621971
     
    DOI:
     
    10.1183/16000617.0066-2015
    [Indexed for MEDLINE] 
    Free full text
  • Ataxia telangiectasia: why should the ERS care?
    हिट्स: 144
    • 2018
    • Zielen S
    • Germany
    • United Kingdom
    • Israel
    • The Netherlands
    • Nissenkorn A
    • Taylor MR
    • Merkus PJFM
    • Bush A
    • Bhatt JM
    • respiration
    • Switzerland
    • Eur Respir J
    • van Gerven M
    • Renke M
    • Yarlett L
    • Tonia T
    • Warris A
    • Zinna S
    Eur Respir J. 2015 Dec;46(6):1557-60. doi: 10.1183/13993003.01456-2015.
    Bhatt JM1, Bush A2, van Gerven M3, Nissenkorn A4, Renke M5, Yarlett L6, Taylor M7, Tonia T8, Warris A9, Zielen S5, Zinna S10, Merkus PJ3.

    Author information

    1
    Nottingham Children's Hospital, UK Paediatric National Clinic, Nottingham University Hospitals NHS Trust, Nottingham, UK jayeshbhatt@hotmail.com.
    2
    Imperial College and Royal Brompton Hospital, London, UK.
    3
    Dept of Paediatrics, Division of Respiratory Medicine, Amalia Children's Hospital, Radboud University Medical Centre, Nijmegen, The Netherlands.
    4
    Rare Diseases Service and Pediatric Neurology Unit, Edmond and Lilly Safra Pediatric Hospital, Sheba Medical Center, Tel Ha Shomer, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
    5
    Dept of Allergology, Pneumology and Cystic Fibrosis, Children's Hospital, Goethe-University Theodor-Stern Kai, Frankfurt/Main, Germany.
    6
    The A-T Society, IACR-Rothamsted, Harpenden, UK.
    7
    School of Cancer Sciences, University of Birmingham, Birmingham, UK.
    8
    Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
    9
    Institute of Medical Sciences, University of Aberdeen and the Royal Aberdeen Children's Hospital, Aberdeen, UK.
    10
    Nottingham Children's Hospital, UK Paediatric National Clinic, Nottingham University Hospitals NHS Trust, Nottingham, UK.
    PMID:
     
    26621885
     
    DOI:
     
    10.1183/13993003.01456-2015
    [Indexed for MEDLINE] 
    Free full text
  • Ataxia telangiectasia.
    हिट्स: 191
    • Israel
    • Nissenkorn A
    • Ben-Zeev B
    • review
    • Handb Clin Neuro
    Handb Clin Neurol. 2015;132:199-214. doi: 10.1016/B978-0-444-62702-5.00014-7.
    Nissenkorn A1, Ben-Zeev B2.

    Author information

     

    Abstract

    Ataxia telangiectasia (AT) is an autosomal recessive multisystem genetic disorder caused by a mutation in the ATM gene encoding for the ATM protein. AT systemic manifestations include cutaneous telangiectasias, radiosensitivity, immune deficiency with recurrent sinopulmonary infections, and a tendency to develop lymphoid malignancies. These complications are explained by the major role played by ATM in DNA repair. AT is also the second most common childhood onset neurodegenerative disorder of the cerebellum, presenting with progressive ataxia and oculomotor apraxia and often accompanied by extrapyramidal movement disorders. Ataxia typically begins around the time children start to walk at about 1 year of age and leads to wheelchair dependence by the second decade of life. Cerebellar atrophy is evident on imaging after 2 years of life and is progressive. Abnormal DNA repair mechanisms do not entirely explain the pathophysiology in nondividing neurons. The nervous system involvement is better explained by the role ATM plays in antioxidative defense, mitochondrial homeostasis, and DNA chromatin packing. A better understanding of the underlying pathophysiologic mechanisms of this devastating disease may enable disease-modifying treatments in the future. Meanwhile, treatment is mainly supportive and does not change the poor prognosis of the disease although it improves the patient's quality of life.

    KEYWORDS:

    ATM; Cerebellar; DNA repair; movement disorder; neurodegeneration

    PMID:
     
    26564081
     
    DOI:
     
    10.1016/B978-0-444-62702-5.00014-7
    [Indexed for MEDLINE]
  • Development of global rating instruments for pediatric patients with ataxia telangiectasia.
    हिट्स: 176
    • Israel
    • Italy
    • India
    • Eur J Paediatr Neurol
    • Nissenkorn A
    • 2016
    • Micheli R
    • SARA scale
    • Ben-Zeev B
    • Molinaro A
    • International Cooperative Ataxia Rating Scale (ICARS)
    • Leuzzi V
    • D'Agnano D
    • Borgohain R
    • Hegde AU
    • Mridula KR
    • Yareeda S
    • Ataxia rating scale
    • BARS
    • CGI
    Eur J Paediatr Neurol. 2016 Jan;20(1):140-6. doi: 10.1016/j.ejpn.2015.09.002. Epub 2015 Sep 25.
    Nissenkorn A1, Borgohain R2, Micheli R3, Leuzzi V4, Hegde AU5, Mridula KR2, Molinaro A3, D'Agnano D4, Yareeda S2, Ben-Zeev B6.

    Author information

    1
    Pediatric Neurology Unit, Edmond and Lilly Safra Pediatric Hospital, Sheba Medical Center, Ramat Gan, Israel; The Service for Rare Diseases, Edmond and Lilly Safra Pediatric Hospital, Sheba Medical Center, Ramat Gan, Israel; The Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. Electronic address: andreea.nissenkorn@sheba.health.gov.il.
    2
    Department Neurology, Nizam's Institute of Medical Sciences, Punjagutta, Hyderabad, India.
    3
    Unit of Child Neurology and Psychiatry, Spedali Civili, Brescia, Italy.
    4
    Department of Pediatrics, Child Neurology and Psychiatry, University of Rome "La Sapienza", Italy.
    5
    Pediatric Neurology, Jaslok Hospital and Research Center, Breach Candy Hospital Trust, Bai Jerbai Wadia Hospital for Children, Mumbai, India.
    6
    Pediatric Neurology Unit, Edmond and Lilly Safra Pediatric Hospital, Sheba Medical Center, Ramat Gan, Israel; The Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

    Abstract

    INTRODUCTION:

    Ataxia telangiectasia (AT) is a neurodegenerative disorder with cerebellar and extrapyramidal features. Interventional and epidemiological studies in AT should rely on specific scales which encompass the specific neurological features, as well the early progressive course and the subsequent plateau. The aim of this study was to build a scale of the CGI type (Clinical Global Impression) which is disease specific, as well as to check the feasibility of the ICARS scale for ataxia in this population.

    METHODS:

    We recruited 63 patients with ataxia, aged 10.76 ± 3.2 years, followed at 6 international AT centers, 49 of them (77.8%) with classical AT. All patients were evaluated for ataxia with ICARS scale. In patients with AT, two CGI scales were scored, unstructured as structured for which separate anchors were provided.

    RESULTS:

    Mean ICARS score was 44.7 ± 20.52, and it's severity positively correlated with age (Spearman correlation, r = 0.46, p < 0.01). Mean CGI score was 2 (moderately involved). There was a high correlation between the structured and unstructured CGIs (Spearman correlation, r = 0.87, p < 0.01). Both CGI scales showed positive correlation between severity and increasing age (Spearman correlation r = 0.59, p < 0.01 for structured CGI and r = 0.61, p < 0.01 for unstructured).

    DISCUSSION:

    We succeeded to build two CGI scales: structured and unstructured, which are disease specific for AT. The unstructured scale showed better connection to disease course; the sensitivity of the unstructured scale could be improved by adding anchors related to extrapyramidal features. In addition we showed that ataxia can be reliably measured in children with AT by using ICARS.

    Copyright © 2015 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved.

    KEYWORDS:

    Ataxia rating scale; BARS; CGI; ICARS; SARA

    PMID:
     
    26493850
     
    DOI:
     
    10.1016/j.ejpn.2015.09.002
    [Indexed for MEDLINE]
  • Targeted Next-Generation Sequencing Revealed Novel Mutations in Chinese Ataxia Telangiectasia Patients: A Precision Medicine Perspective.
    हिट्स: 279
    • China
    • 2015
    • Next-generation sequencing
    • PLoS One
    • ATM mutations
    • Chen Z
    • Ye W
    • Long Z
    • Ding D
    • Peng H
    • Hou X
    • Qiu R
    • Xia K
    • Tang B
    • Jiang H
    PLoS One. 2015 Oct 6;10(10):e0139738. doi: 10.1371/journal.pone.0139738. eCollection 2015.

    Chen Z1, Ye W1, Long Z1, Ding D1, Peng H1, Hou X1, Qiu R2, Xia K3, Tang B4, Jiang H4.

    Author information

    1
    Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, P.R. China.
    2
    School of Information Science and Engineering, Central South University, Changsha, Hunan, P.R. China.
    3
    State Key Laboratory of Medical Genetics, Central South University, Changsha, Hunan, P.R. China.
    4
    Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, P.R. China; Key Laboratory of Hunan Province in Neurodegenerative Disorders, Central South University, Changsha, Hunan, P.R. China; State Key Laboratory of Medical Genetics, Central South University, Changsha, Hunan, P.R. China.

    Abstract

    Ataxia telangiectasia (AT) is an autosomal recessive disease characterized by progressive cerebellar ataxia, oculocutaneous telangiectasia and immunodeficiency due to mutations in the ATM gene. We performed targeted next-generation sequencing (NGS) on three unrelated patients and identified five disease-causing variants in three probands, including two pairs of heterozygous variants (FAT-1:c.4396C>T/p.R1466X, c.1608-2A>G; FAT-2:c.4412_4413insT/p.L1472Ffs*19, c.8824C>T/p.Q2942X) and one pair of homozygous variants (FAT-3: c.8110T>G/p.C2704G, Hom). With regard to precision medicine for rare genetic diseases, targeted NGS currently enables the rapid and cost-effective identification of causative mutations and is an updated molecular diagnostic tool that merits further optimization. This high-throughput data-based strategy would propel the development of precision diagnostic methods and establish a foundation for precision medicine.

    PMID:
     
    26439923
     
    PMCID:
     
    PMC4595474
     
    DOI:
     
    10.1371/journal.pone.0139738
    [Indexed for MEDLINE] 
    Free PMC Article
  • Motor pathway degeneration in young ataxia telangiectasia patients: A diffusion tractography study.
    हिट्स: 206
    • ataxia telangiectasia
    • Italy
    • 2015
    • Sinclair K
    • Lavin MF
    • Australia
    • cerebellum
    • Neuroimage Clin
    • Sahama I
    • Fiori S
    • Doecke J
    • Pannek K
    • Reid L
    • Rose S
    • Diffusion magnetic resonance imaging
    • Whole tract statistics
    Neuroimage Clin. 2015 Aug 20;9:206-15. doi: 10.1016/j.nicl.2015.08.007. eCollection 2015.
    Sahama I1, Sinclair K2, Fiori S3, Doecke J4, Pannek K5, Reid L4, Lavin M6, Rose S4.

    Author information

    1
    University of Queensland, School of Medicine, Brisbane, Australia.
    2
    Neurology, The Royal Children's Hospital, Brisbane, Australia.
    3
    IRCCS Stella Maris, Calambrone, Pisa, Italy.
    4
    Digital Productivity Flagship/The Australian E-Health Research Centre, Commonwealth Scientific and Industrial Research Organization, Brisbane, Australia.
    5
    Imperial College London, London, United Kingdom.
    6
    University of Queensland Centre for Clinical Research, Brisbane, Australia.

    Abstract

    BACKGROUND:

    Our understanding of the effect of ataxia-telangiectasia mutated gene mutations on brain structure and function is limited. In this study, white matter motor pathway integrity was investigated in ataxia telangiectasia patients using diffusion MRI and probabilistic tractography.

    METHODS:

    Diffusion MRI were obtained from 12 patients (age range: 7-22 years, mean: 12 years) and 12 typically developing age matched participants (age range 8-23 years, mean: 13 years). White matter fiber tracking and whole tract statistical analyses were used to assess quantitative fractional anisotropy and mean diffusivity differences along the cortico-ponto-cerebellar, cerebellar-thalamo-cortical, somatosensory and lateral corticospinal tract length in patients using a linear mixed effects model. White matter tract streamline number and apparent fiber density in patient and control tracts were also assessed.

    RESULTS:

    Reduced fractional anisotropy along all analyzed patient tracts were observed (p < 0.001). Mean diffusivity was significantly elevated in anterior tract locations but was reduced within cerebellar peduncle regions of all patient tracts (p < 0.001). Reduced tract streamline number and tract volume in the left and right corticospinal and somatosensory tracts were observed in patients (p < 0.006). In addition, reduced apparent fiber density in the left and right corticospinal and right somatosensory tracts (p < 0.006) occurred in patients.

    CONCLUSIONS:

    Whole tract analysis of the corticomotor, corticospinal and somatosensory pathways in ataxia telangiectasia showed significant white matter degeneration along the entire length of motor circuits, highlighting that ataxia-telangiectasia gene mutation impacts the cerebellum and multiple other motor circuits in young patients.

    KEYWORDS:

    Ataxia telangiectasia; Cerebellum; Diffusion magnetic resonance imaging; Whole tract statistics

    PMID:
     
    26413479
     
    PMCID:
     
    PMC4561673
     
    DOI:
     
    10.1016/j.nicl.2015.08.007
    [Indexed for MEDLINE] 
    Free PMC Article
  • Ataxia-Telangiectasia Presenting as Cerebral Palsy and Recurrent Wheezing: A Case Report.
    हिट्स: 226
    • 2015
    • Am J Case Rep
    • Croatia
    • Navratil M
    • Đuranović V
    • Nogalo B
    • Švigir A
    • Dumbović Dubravčić I
    • Turkalj M
    • misdiagnosis
    • Cerebral Palsy
    Am J Case Rep. 2015 Sep 18;16:631-6. doi: 10.12659/AJCR.893995.
    Navratil M1, Đuranović V2, Nogalo B1, Švigir A3, Dumbović Dubravčić I3, Turkalj M1.

    Author information

    1
    Department of Allergy and Immunology, Srebrnjak Children's Hospital, Zagreb, Croatia.
    2
    Department of Neurology, Zagreb Children's Hospital, Zagreb, Croatia.
    3
    Department of Allergy and Pulmonology, Srebrnjak Children's Hospital, Zagreb, Croatia.

    Abstract

    BACKGROUND:

    Ataxia-telangiectasia (A-T) is an autosomal recessive disease that consists of progressive cerebellar ataxia, variable immunodeficiency, sinopulmonary infections, oculocutaneous telangiectasia, radiosensitivity, early aging, and increased incidence of cancer.

    CASE REPORT:

    We report the case of an 8-year-old boy affected by A-T. At 12 months of age, he had a waddling gait, with his upper body leaning forward. Dystonic/dyskinetic cerebral palsy was diagnosed at the age of 3 years. At age 6 he was diagnosed with asthma based on recurrent wheezing episodes. A-T was confirmed at the age 8 years on the basis of clinical signs and laboratory findings (increased alpha fetoprotein--AFP, immunodeficiency, undetectable ataxia-telangiectasia mutated (ATM) protein on immunoblotting, and identification A-T mutation, 5932G>T).

    CONCLUSIONS:

    The clinical and immunological presentation of ataxia-telangiectasia (A-T) is very heterogeneous and diagnostically challenging, especially at an early age, leading to frequent misdiagnosis.

    PMID:
     
    26380989
     
    PMCID:
     
    PMC4578644
     
    DOI:
     
    10.12659/AJCR.893995
    [Indexed for MEDLINE] 
    Free PMC Article

पृष्ठ 5 का 19

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10

Language

  Hindi (India)
  • Hindi (India)
  • Hebrew
  • Arabic (اللغة العربية)
  • Turkish (Turkey)
  • 日本語 (Japan)
  • Russian (Russia)
  • Français (France)
  • Deutsch (Deutschland)
  • Español (España)
  • Nederlands (nl-NL)
  • Português Brasileiro (pt-BR)
  • Polski (PL)
  • Italiano (Italia)
  • English (United Kingdom)

Tweets by A_Tinfo

गतिभंग रक्त वाहिनी विस्तार
  • शुरू
  • ए-टी क्या है?
  • admin@ataxiatelangiectasia.es